Family Medicine and the “New” Opioid Epidemic

References

1. 1.↵
   1. Peterson LE,
   2. Morgan ZJ,
   3. Borders TF

   . Practice predictors of buprenorphine prescribing by family physicians. J Am Board Fam Med 2020;33:118–123.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Peterson LE,
   2. Morgan ZJ,
   3. Eden AR

   . Early-career and graduating physicians more likely to prescribe buprenorphine. J Am Board Fam Med 2020;33:7–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Abraham R,
   2. Wilkinson E,
   3. Jabbarpour Y,
   4. Petterson S,
   5. Bazemore A

   . Characteristics of office-based buprenorphine prescribers for Medicare patients. J Am Board Fam Med 2020;33:9–16.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Sokol R,
   2. Schuman-Olivier Z,
   3. Batalden M,
   4. Sullivan L,
   5. Shaughnessy AF

   . A change management case study for safe opioid prescribing and opioid use disorder treatment. J Am Board Fam Med 2020;33:129–137.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. van Eeghen C,
   2. Kennedy AG,
   3. Pasanen ME,
   4. MacLean CD

   . A new quality improvement toolkit to improve opioid prescribing in primary care. J Am Board Fam Med 2020;33:17–26.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Breeden MA,
   2. Jacobs CK,
   3. Witthaus M,
   4. et al

   . Prescribing patterns and use of risk-reduction tools after implementing an opioid-prescribing protocol. J Am Board Fam Med 2020;33:27–33.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Raad M,
   2. Pakpoor J,
   3. Harris A,
   4. et al

   . Opioid prescriptions for new low back pain: trends and variability by state. J Am Board Fam Med 2020;33:138–142.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Jerant A,
   2. Agnoli A,
   3. Franks P

   . Satisfaction with health care among prescription opioid recipients. J Am Board Fam Med 2020;33:34–41.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Diiulio J,
   2. Militello L,
   3. Andraka-Christou BT,
   4. et al

   . Factors that influence changes to existing chronic pain management plans. J Am Board Fam Med 2020;33:42–50.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Magnan EM,
    2. Franks P,
    3. Jerant A,
    4. Kravitz RL,
    5. Fenton JJ

    . When physicians say no: predictors of request denial and subsequent patient satisfaction. J Am Board Fam Med 2020;33:51–58.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Redinger M,
    2. Fledderman N,
    3. Crutchfield P

    . An ethical framework to manage patient requests for medical marijuana. J Am Board Fam Med 2020;33:147–151.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Loskutova N,
    2. Waterman J,
    3. Callen E,
    4. Staton EW,
    5. Bullard E,
    6. Shields J

    . Knowledge, attitudes and practice patterns of health professionals toward medical and non-medical stimulant use by young adults. J Am Board Fam Med 2020;33:59–70.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Purkaple BA,
    2. Nagykaldi ZJ,
    3. Allahyar A,
    4. Todd R,
    5. Mold JW

    . Physicians' response to patients' quality-of-life goals. J Am Board Fam Med 2020;33:71–79.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Brodney S,
    2. Fowler FJ Jr.,
    3. Stringfellow V,
    4. Valentine KD,
    5. Barry MJ

    . National survey of decision-making for antidepressants and educational level. J Am Board Fam Med 2020;33:80–90.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Crego N,
    2. Douglas C,
    3. Bonnabeau E,
    4. et al

    . Sickle cell disease co-management, health care utilization and hydroxyurea use. J Am Board Fam Med 2020;33:91–105.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Moerenhout T,
    2. Fischer GS,
    3. Saelaert M,
    4. De Sutter A,
    5. Provoost V,
    6. Devisch I

    . Primary care physicians' perspectives on the ethical impact of the electronic medical record. J Am Board Fam Med 2020;33:106–117.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Johansen ME,
    2. Yun J,
    3. Griggs JM,
    4. Jackson EA,
    5. Richardson CR

    . Anti-hypertensive medication combinations in the United States. J Am Board Fam Med 2020;33:143–146.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Ettienne EB,
    2. Ofoegbu A,
    3. Maneno MK,
    4. et al

    . Pharmacogenomics and OUD: clinical decision support in an African American cohort. J Natl Med Assoc. 2019 [Epub ahead of print].
19. 19.↵
    1. Farrar M,
    2. White Z,
    3. Hulkower S,
    4. Fagan EB,
    5. Gilmore Wilson C

    . A financial model for team-based opioid use disorder treatment. J Am Board Fam Med 2020;33:124–128.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    University of New Mexico School of Medicine. Project ECHO. Available from: https://echo.unm.edu/. Accessed November 21, 2019.